{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T13:46:33Z","timestamp":1762004793839,"version":"build-2065373602"},"reference-count":53,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1016\/j.urolonc.2016.03.011","type":"journal-article","created":{"date-parts":[[2016,4,30]],"date-time":"2016-04-30T17:06:13Z","timestamp":1462035973000},"page":"271-278","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Chemoradiation for organ preservation in the treatment of muscle-invasive bladder cancer"],"prefix":"10.1016","volume":"34","author":[{"given":"Derek R.","family":"McHaffie","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim J.","family":"Kruser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kris","family":"Gaston","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Mahoney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Graham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Haake","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2016.03.011_bib1","first-page":"5","article-title":"Cancer statistics, 2015","volume":"65","author":"Siegel","year":"2015","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.urolonc.2016.03.011_bib2","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1016\/S0140-6736(03)13580-5","article-title":"Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis","volume":"361","author":"Advanced Bladder Cancer Meta-analysis C","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.urolonc.2016.03.011_bib3","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.urology.2006.01.051","article-title":"Complications after radical cystectomy: analysis of population-based data","volume":"68","author":"Konety","year":"2006","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2016.03.011_bib4","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1016\/S0022-5347(05)65074-4","article-title":"Analysis of early complications after radical cystectomy: results of a collaborative care pathway","volume":"167","author":"Chang","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2016.03.011_bib5","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0022-5347(05)64045-1","article-title":"Complications of radical cystectomy for nonmuscle invasive disease: comparison with muscle invasive disease","volume":"169","author":"Cookson","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2016.03.011_bib6","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.eururo.2006.06.014","article-title":"Perioperative complications of radical cystectomy in a contemporary series","volume":"51","author":"Novotny","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2016.03.011_bib7","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1002\/cncr.22556","article-title":"Measuring health-related quality of life outcomes in bladder cancer patients using the Bladder Cancer Index (BCI)","volume":"109","author":"Gilbert","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2016.03.011_bib8","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1200\/JCO.2001.19.3.666","article-title":"Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients","volume":"19","author":"Stein","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2016.03.011_bib9","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1111\/j.1464-410X.2010.09537.x","article-title":"Group STM: Life and death of spare (selective bladder preservation against radical excision): reflections on why the spare trial closed","volume":"106","author":"Huddart","year":"2010","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2016.03.011_bib10","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/j.ijrobp.2014.01.001","article-title":"Clinical-pathologic stage discrepancy in bladder cancer patients treated with radical cystectomy: results from the national cancer data base","volume":"88","author":"Gray","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.urolonc.2016.03.011_bib11","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1159\/000020294","article-title":"Long-term risk of salvage cystectomy after radiotherapy for muscle-invasive bladder cancer","volume":"38","author":"Cooke","year":"2000","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2016.03.011_bib12","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1200\/JCO.1996.14.11.2901","article-title":"Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. The National Cancer Institute of Canada Clinical Trials Group","volume":"14","author":"Coppin","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2016.03.011_bib13","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1200\/JCO.2014.57.5548","article-title":"Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233","volume":"32","author":"Mak","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2016.03.011_bib14","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1016\/j.juro.2006.08.004","article-title":"Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium","volume":"176","author":"Shariat","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2016.03.011_bib15","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.eururo.2011.11.010","article-title":"Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience","volume":"61","author":"Efstathiou","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2016.03.011_bib16","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/j.ijrobp.2007.01.054","article-title":"Radiochemotherapy with cisplatin and 5-fluorouracil after transurethral surgery in patients with bladder cancer","volume":"68","author":"Weiss","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.urolonc.2016.03.011_bib17","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1023\/A:1011133820532","article-title":"A phase I-II study of synchronous chemoradiotherapy for poor prognosis locally advanced bladder cancer","volume":"12","author":"Hussain","year":"2001","journal-title":"Ann Oncol"},{"key":"10.1016\/j.urolonc.2016.03.011_bib18","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1056\/NEJMoa1106106","article-title":"Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer","volume":"366","author":"James","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2016.03.011_bib19","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1200\/JCO.2010.31.5721","article-title":"Phase II study of conformal hypofractionated radiotherapy with concurrent gemcitabine in muscle-invasive bladder cancer","volume":"29","author":"Choudhury","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2016.03.011_bib20","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.ijrobp.2004.05.074","article-title":"Phase I study of conformal radiotherapy with concurrent gemcitabine in locally advanced bladder cancer","volume":"61","author":"Sangar","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.urolonc.2016.03.011_bib21","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s12094-013-1047-8","article-title":"Concurrent chemoradiotherapy with low dose weekly gemcitabine in medically inoperable muscle-invasive bladder cancer patients","volume":"16","author":"Atasoy","year":"2014","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.urolonc.2016.03.011_bib22","doi-asserted-by":"crossref","first-page":"3576","DOI":"10.1200\/JCO.1998.16.11.3576","article-title":"Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03","volume":"16","author":"Shipley","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2016.03.011_bib23","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.urology.2012.07.045","article-title":"Long-term results of two prospective bladder-sparing trimodality approaches for invasive bladder cancer: neoadjuvant chemotherapy and concurrent radio-chemotherapy","volume":"80","author":"Zapatero","year":"2012","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2016.03.011_bib24","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1634\/theoncologist.5-6-471","volume":"5","author":"Kaufman","year":"2000","journal-title":"Oncologist"},{"key":"10.1016\/j.urolonc.2016.03.011_bib25","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0360-3016(03)00718-1","article-title":"RTOG 97-06: initial report of a phase I-II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy","volume":"57","author":"Hagan","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.urolonc.2016.03.011_bib26","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.urology.2008.09.036","article-title":"Phase I-II RTOG study (99-06) of patients with muscle-invasive bladder cancer undergoing transurethral surgery, paclitaxel, cisplatin, and twice-daily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapy","volume":"73","author":"Kaufman","year":"2009","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2016.03.011_bib27","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.ijrobp.2013.11.211","article-title":"Occult pelvic lymph node involvement in bladder cancer: implications for definitive radiation","volume":"88","author":"Goldsmith","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.urolonc.2016.03.011_bib28","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0090-4295(02)02116-7","article-title":"Extent of surgery and pathology evaluation has an impact on bladder cancer outcomes after radical cystectomy","volume":"61","author":"Herr","year":"2003","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2016.03.011_bib29","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1016\/j.juro.2007.05.160","article-title":"Radical cystectomy and extended pelvic lymphadenectomy: survival of patients with lymph node metastasis above the bifurcation of the common iliac vessels treated with surgery only","volume":"178","author":"Steven","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2016.03.011_bib30","doi-asserted-by":"crossref","first-page":"e457","DOI":"10.1016\/j.ijrobp.2011.05.051","article-title":"Whole-pelvis or bladder-only chemoradiation for lymph node-negative invasive bladder cancer: single-institution experience","volume":"82","author":"Tunio","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.urolonc.2016.03.011_bib31","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/01.ju.0000163267.93769.d8","article-title":"Prognostic significance of lymphovascular invasion of bladder cancer treated with radical cystectomy","volume":"174","author":"Quek","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2016.03.011_bib32","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/j.1464-410X.2008.08011.x","article-title":"The significance of lymphovascular invasion in transurethral resection of bladder tumour and cystectomy specimens on the survival of patients with urothelial bladder cancer","volume":"103","author":"Streeper","year":"2009","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2016.03.011_bib33","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S0360-3016(01)01510-3","article-title":"The impact of gap duration on local control in anal canal carcinoma treated by split-course radiotherapy and concomitant chemotherapy","volume":"50","author":"Weber","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.urolonc.2016.03.011_bib34","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1097\/00005537-199612000-00020","article-title":"The effect of overall treatment time of radiation therapy on local control of T1-stage squamous cell carcinoma of the glottis","volume":"106","author":"Hayakawa","year":"1996","journal-title":"Laryngoscope"},{"key":"10.1016\/j.urolonc.2016.03.011_bib35","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1093\/jjco\/27.4.240","article-title":"Split-course accelerated hyperfractionation radiotherapy for advanced head and neck cancer: influence of split time and overall treatment time on local control","volume":"27","author":"Akimoto","year":"1997","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.urolonc.2016.03.011_bib36","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.radonc.2010.03.020","article-title":"The role of overall treatment time in the outcome of radiotherapy of prostate cancer: an analysis of biochemical failure in 4839 men treated between 1987 and 1995","volume":"96","author":"Thames","year":"2010","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.urolonc.2016.03.011_bib37","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S0360-3016(98)00263-6","article-title":"Muscle-invasive bladder cancer treated with external beam radiation: influence of total dose, overall treatment time, and treatment interruption on local control","volume":"42","author":"Moonen","year":"1998","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.urolonc.2016.03.011_bib38","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.ijrobp.2003.10.018","article-title":"Radiotherapy for muscle-invasive carcinoma of the bladder: results of a randomized trial comparing conventional whole bladder with dose-escalated partial bladder radiotherapy","volume":"59","author":"Cowan","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.urolonc.2016.03.011_bib39","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.ijrobp.2013.06.2044","article-title":"Randomized noninferiority trial of reduced high-dose volume versus standard volume radiation therapy for muscle-invasive bladder cancer: results of the BC2001 trial (CRUK\/01\/004)","volume":"87","author":"Huddart","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.urolonc.2016.03.011_bib40","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.hoc.2014.10.004","article-title":"Bladder preservation strategies","volume":"29","author":"Jani","year":"2015","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.urolonc.2016.03.011_bib41","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1200\/JCO.2006.05.8149","article-title":"Radiochemotherapy after transurethral resection for high-risk T1 bladder cancer: an alternative to intravesical therapy or early cystectomy?","volume":"24","author":"Weiss","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2016.03.011_bib42","doi-asserted-by":"crossref","first-page":"4055","DOI":"10.1200\/JCO.2008.19.5776","article-title":"Late pelvic toxicity after bladder-sparing therapy in patients with invasive bladder cancer: RTOG 89-03, 95-06, 97-06, 99-06","volume":"27","author":"Efstathiou","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2016.03.011_bib43","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1200\/JCO.2002.11.027","article-title":"Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results","volume":"20","author":"Rodel","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2016.03.011_bib44","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/S0090-4295(02)01650-3","article-title":"Selective bladder preservation by combined modality protocol treatment: long-term outcomes of 190 patients with invasive bladder cancer","volume":"60","author":"Shipley","year":"2002","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2016.03.011_bib45","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1097\/01.ju.0000093721.23249.c3","article-title":"Organ conservation in invasive bladder cancer by transurethral resection, chemotherapy and radiation: results of a urodynamic and quality of life study on long-term survivors","volume":"170","author":"Zietman","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2016.03.011_bib46","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1200\/JCO.2004.10.070","article-title":"Combined-modality therapy with gemcitabine and radiotherapy as a bladder preservation strategy: results of a phase I trial","volume":"22","author":"Kent","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2016.03.011_bib47","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ijrobp.2004.09.047","volume":"62","author":"Chakravarti","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.urolonc.2016.03.011_bib48","doi-asserted-by":"crossref","first-page":"7017","DOI":"10.1158\/0008-5472.CAN-10-1202","article-title":"MRE11 expression is predictive of cause-specific survival following radical radiotherapy for muscle-invasive bladder cancer","volume":"70","author":"Choudhury","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.urolonc.2016.03.011_bib49","doi-asserted-by":"crossref","first-page":"E1228","DOI":"10.1111\/j.1464-410X.2012.11564.x","article-title":"Expression of TIP60 (tat-interactive protein) and MRE11 (meiotic recombination 11 homolog) predict treatment-specific outcome of localised invasive bladder cancer","volume":"110","author":"Laurberg","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2016.03.011_bib50","doi-asserted-by":"crossref","first-page":"4912","DOI":"10.1200\/JCO.2010.28.4950","article-title":"Radiotherapy with concurrent carbogen and nicotinamide in bladder carcinoma","volume":"28","author":"Hoskin","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2016.03.011_bib51","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.radonc.2013.05.017","article-title":"Necrosis predicts benefit from hypoxia-modifying therapy in patients with high risk bladder cancer enrolled in a phase III randomised trial","volume":"108","author":"Eustace","year":"2013","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.urolonc.2016.03.011_bib52","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/bjc.2014.315","article-title":"Expression of hypoxia-inducible factor-1alpha predicts benefit from hypoxia modification in invasive bladder cancer","volume":"111","author":"Hunter","year":"2014","journal-title":"Br J Cancer"},{"key":"10.1016\/j.urolonc.2016.03.011_bib53","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/bjc.2013.744","article-title":"Urinary EpCAM in urothelial bladder cancer patients: characterisation and evaluation of biomarker potential","volume":"110","author":"Bryan","year":"2014","journal-title":"Br J Cancer"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143916000934?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143916000934?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:07:57Z","timestamp":1761041277000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143916000934"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":53,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["S1078143916000934"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2016.03.011","relation":{},"ISSN":["1078-1439"],"issn-type":[{"type":"print","value":"1078-1439"}],"subject":[],"published":{"date-parts":[[2016,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chemoradiation for organ preservation in the treatment of muscle-invasive bladder cancer","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2016.03.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}